News
Novo Nordisk shares dip further as Wegovy gains nearly erased
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago.
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
Wegovy, the blockbuster weight-loss drug, is now available in Singapore more than two years after it was approved by the ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback